You Deserve Every Option.

See if You Qualify for our Leptomeningeal Metastases Clinical Trial

Trial Information

Leptomeningeal Metastases (LM) is sometimes referred to as leptomeningeal cancer, leptomeningeal disease, neoplastic meningitis, or meningeal carcinomatosis. This rare but serious condition happens when cancer cells spread to the membranes surrounding the brain and spinal cord. Leptomeningeal Metastases is most commonly found in patients with melanoma, breast, lung, or gastrointestinal cancer. Unfortunately, there are no FDA approved treatments specifically for Leptomeningeal Metastases.

Plus Therapeutics is developing a new targeted radiation therapy, REYOBIQ™ (rhenium Re186 obisbemeda), for central nervous system cancers such as Leptomeningeal Metastases. In the U.S. ReSPECT-LM clinical trial, doctors will give Leptomeningeal Metastases patients REYOBIQ™ through a small catheter placed under the patient’s scalp. This drug will be administered in less than 5 minutes in a hospital setting and the patient will go home the same day.

The ReSPECT-LM clinical trial is funded, in part, by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas, the second largest public funding source for cancer research in the world.

View Trial on ClinicalTrials.gov

NATIONAL TRIAL REFERENCE NUMBER

NCT07098806

Patients Treated to Date

Patient Eligibility

Only a qualified healthcare professional can determine whether or not you are eligible to participate in a clinical trial. However, this information may be beneficial in initiating a conversation with your physician. Full patient eligibility will be discussed upon patient screening.

Age Range

Adults, 18 years and older

Condition

Leptomeningeal Metastases from any solid tumor cancers (i.e. breast, lung, melanoma, gastrointestinal)

Prior Treatment

No prior whole brain or spinal cord radiation therapy

l

Informed Consent

Able to understand the study purposes and risks

Gender

All; Women have negative pregnancy test at screening; Subjects must use effective contraception during study

Principal Investigators

There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.

Andrew Brenner, M.D., Ph.D.

UT Health San Antonio, Mays Cancer Center

San Antonio, Texas

About Dr. Brenner

Previously Enrolled

as part of the ReSPECT-LM single-dose clinical trial:

Michael Youssef, M.D.

UT Southwestern Medical Center

Priya Kumthekar, M.D.

Northwestern Memorial Hospital

Michael Schulder, M.D.

North Shore University Hospital

Pierre Giglio, M.D.

The Ohio State University Cancer Center

Randy S. D’Amico, M.D.

Lenox Hill Hospital

Trial Locations

Please visit this website regularly for updates as new locations are added.

UT Health Science Center

San Antonio

Previously Enrolled

as part of the ReSPECT-LM single-dose clinical trial:

UT Southwestern Medical Center – Dallas

Northwestern Memorial Hospital – Chicago

North Shore University Hospital – New York

Ohio State University – Columbus

Lenox Hill Hospital – New York

What Can You Do Next?

Participating in a clinical trial is an important decision. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Discuss With Your Physician

Anyone participating in a clinical trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your physician first.

Print, save, or email this page to your physician to discuss at your next visit

Contact A Trial Coordinator

A trial coordinator is a specialized researcher who supports the management and coordination of clinical research studies. If you are interested in participating in a clinical trial, you may call a trial coordinator directly at one of the trial locations below.

UT Health Science Center
San Antonio

Leticia Velten
 210-450-1921
 velten@uthscsa.edu

Contact Us

Request More Information

News

December 3, 2024

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Publications

Posters

Brenner, Andrew et al. “Rhenium Obisbemeda (Reyobiq) in Leptomeningeal Metastases.” Nuclear Medicine and Neurooncology Symposium 2025.

Brenner, Andrew et al. “Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for the Treatment of Leptomeningeal Metastases (LM): Update on Phase 1 Dose Escalation Study.” SABCS 2024.

Brenner, Andrew et al. “Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for the Treatment of Leptomeningeal Metastases (LM): Summary of the Phase 1 Dose Escalation Study and Phase 2 Administered Dose Selection .” SNO Annual Meeting 2024.

Bao, Ande et al. “Radiation Absorbed Dose to Spinal Cord:Therapy of Leptomeningeal Metastasis Using Beta-Emission Radiopharmacauticals.” SNO/ASCO CNS Metastases Conference 2024.

Brenner, Andrew et al. “Update Report of the ReSPECT Trials: Treatment of Recurrent Glioblastoma and Leptomeningeal Metastases with Rhenium (186Re) Obisbemeda.” NMN Precision Medicine Symposium 2024.

Brenner, Andrew et al. “Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases Phase 1 Dose Escalation Trial: Update of Initial Safety and Feasibility.” NCCN Annual 2024.

Brenner, Andrew et al. “Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases Phase 1 Dose Escalation Trial: Initial Safety and Feasibility.” SNO Annual Meeting 2023.

Brenner, Andrew et al. “Phase 1A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM).” Cancer Prevention & Research Institute of Texas (CPRIT) Innovations 2023.

Brenner, Andrew et al. “Preliminary Clinical Data in the Phase 1/2a Dose Escalation Trial of Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM): The ReSPECT-LM Trial.” SNO/ASCO CNS Cancer Conference 2023.

LaFrance, Norman et al. “Preclinical and Preliminary Clinical Data in the Phase 1/2a Dose Escalation Trial of 186RNL (Rhenium-186 Nanoliposome) (186Re) Obisbemeda in Leptomeningeal Metastases (LM): The ReSPECTTM-LM Trial.” SNMMI Annual Meeting 2023.

Presentations

Reimagining Your Approach to Leptomeningeal Metastases, SNO/ASCO CNS Metastases Conference, August 14, 2025

Novel Targeted Radiotherapies to Manage Leptomeningeal Metastases, SNO Annual ISS Symposium, November 23, 2024

Phase 1 Dose Escalation of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for the Treatment of Leptomeningeal Metastases (LM), SNO/ASCO CNS Metastases Conference Oral Presentation, August 8, 2024

Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases, SNO/ASCO CNS Metastases Independent Symposium, August 8, 2024

Targeted Radiolabeled Nanoliposomes for Rare CNS Cancers: An Update on the ReSPECT Phase 1/2 Trials, Gordon Research Conference, July 8, 2024

Phase 1A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM), Cancer Prevention & Research Institute of Texas (CPRIT) Innovations Conference, October 3, 2023

KOL Roundtable on Leptomeningeal Metastases: An Obvious Disease Target for Radiotherapeutic Intervention, SNO/ASCO CNS Cancer Conference, August 11, 2023

Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1/2a Trial, EANM Congress, October 19, 2022

Resources

Note: all external links

Updates

Positive ReSPECT-LM Phase 1 Data at SNO/ASCO CNS Metastases Conference

Plus Therapeutics (NASDAQ: PSTV) announced positive data from the ReSPECT-LM Phase 1 single dose escalation clinical trial, presented at the podium during the Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference....

CNSide® CSF Assay Platform at 2025 SNO/ASCO CNS Metastases Conference

Plus Therapeutics (NASDAQ: PSTV) presented encouraging data from a retrospective analysis of the CNSide® Cerebrospinal Fluid (CSF) Assay Platform at the 2025 Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference in...

Leading Experts in Leptomeningeal Metastases to Present at SNO/ASCO CNS Metastases Conference

Leptomeningeal Metastases (LM) is a devastating complication of advanced cancers, where cancer cells spread to the cerebrospinal fluid and leptomeninges of the brain and spinal cord. Research and collaboration are critical to improving outcomes for patients facing...

Join Us at the 2025 SNO/ASCO CNS Metastases Conference for a Spotlight Symposium on Leptomeningeal Metastases

Mark your calendars!Date: Thursday, August 14, 2025Time: 6:15 PM ESTLocation: Baltimore Waterfront Marriott, Baltimore, MD We are proud to invite you to a compelling educational symposium at the 2025 SNO/ASCO CNS Metastases Conference, where leading voices in...

« Older Entries

Next Entries »

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.